Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
03.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
01.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib | 54 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced... ► Artikel lesen | |
24.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit | 2 | GlobeNewswire (USA) | ||
23.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 | 1 | GlobeNewswire (USA) | ||
23.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | Cullinan Therapeutics files to sell 14.4M shares of common stock for holders | 1 | Seeking Alpha | ||
16.05. | Cullinan Oncology reports Q1 results | 1 | Seeking Alpha | ||
15.05. | Cullinan Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | - | Reuters | ||
15.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | 239 | GlobeNewswire (Europe) | Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases... ► Artikel lesen | |
29.04. | Cullinan Therapeutics appoints CFO | 1 | Seeking Alpha | ||
29.04. | Cullinan Therapeutics Appoints Fenton As CFO | - | RTTNews | ||
29.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | 180 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
29.04. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.04. | PEGY, CGEM and IFBD among mid-day movers | 7 | Seeking Alpha | ||
24.04. | Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? | 4 | Benzinga.com | ||
24.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors ... | 2 | GlobeNewswire (USA) | ||
16.04. | Cullinan Therapeutics Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity | 2 | Benzinga.com | ||
16.04. | Cullinan Oncology changes name, pivots to autoimmune disease | 4 | BioPharma Dive | ||
16.04. | Cullinan Oncology rebrands, halts lymphoma trial to reflect autoimmune refocus | 4 | FierceBiotech |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 67,85 | +0,07 % | Schock-News für Morphosys Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
MODERNA | 111,52 | +0,13 % | Verlustreicher Tag für Moderna-Aktionäre: Aktienkurs sinkt deutlich (107,7255 €) | Zu den großen Verlierern an der Börse zählt am Mittwoch die Moderna-Aktie . Das Wertpapier verbilligt sich heute deutlich. Mit einem Minus von 3,55 Prozent gehört heute das Wertpapier von Moderna zu... ► Artikel lesen | |
VALNEVA | 3,292 | +0,12 % | Valneva-Aktie +6%: Das bringt neuen Schwung | Nach einer scharfen Korrektur am Freitag springt die Valneva-Aktie (WKN: A0MVJZ) am Montagmorgen um knapp +6% auf 3,48€. Eine bedeutende Finanzspritze sorgt für neue Impulse. Kann der Biotech-Titel... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
INOVIO PHARMACEUTICALS | 10,280 | -1,34 % | INOVIO Pharmaceuticals, Inc.: Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 | Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,825 | +4,02 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate | Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today... ► Artikel lesen | |
INFLARX | 1,417 | +1,50 % | InflaRx N.V.: InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign | ||
INTELLIA THERAPEUTICS | 24,570 | +0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
VIVORYON THERAPEUTICS | 2,385 | -1,45 % | Vivoryon mit Neuausrichtung: Aktie legt weiter zu - das ist geplant | Die Aktie des früheren Alzheimer-Hoffnungsträgers Vivoryon hat zuletzt erneut zulegen können. Das deutsche Biotech-Unternehmen arbeitet derzeit an einer strategischen Neuausrichtung. Zukünftig will... ► Artikel lesen | |
VIKING THERAPEUTICS | 60,42 | -0,53 % | Adipositas-Hoffnung Viking Therapeutics: Aktie mit 24-Prozent-Kurssprung - was ist da los? | Die Aktie des US-Biotech-Unternehmens Viking Therapeutics hat am Mittwoch nach US-Börsenschluss einen kräftigen Kurssprung von 24 Prozent hinlegen können. Das Unternehmen, das insbesondere als großer... ► Artikel lesen | |
EDITAS MEDICINE | 5,322 | +2,35 % | Editas Medicine, Inc.: Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress | All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was... ► Artikel lesen |